12 Jun. 2019
Stuart Therapeutics, Inc. Announces a Strategic Partnership with Ora, Inc.

STUART, FLORIDA June 12, 2019: Stuart Therapeutics, Inc. (STUART), an innovative pre-clinical ophthalmic therapeutic development company, today announces it has entered into a strategic partnership with Ora®, Inc. (“ORA”), the premier global ophthalmology contract research organization.  ORA is investing in its partnership with STUART by providing CMC program execution, IND preparation, and related strategic consulting

Read More
22 Apr. 2019
Stuart Therapeutics Announces Positive Retinal Indication in vitro Results for PolyCol

April 22nd, 2019, Stuart, Florida For Immediate Release Stuart Therapeutics, Inc., a pre-clinical stage life sciences company developing solutions for difficult to treat ophthalmic diseases, today announced positive results from in vitro experiments using its proprietary collagen mimetic peptide (CMP), PolyColTM (PolyCol) to probe applicability for conditions associated with dry age-related macular degeneration (Dry AMD). 

Read More
03 Apr. 2019
Stuart Therapeutics Receives Positive Response in Pre-IND Meeting with FDA for its Dry Eye Disease Therapeutic Candidate, ST-100

April 3rd, 2019, Stuart, Florida For Immediate Release Stuart Therapeutics, Inc. (Stuart), a pre-clinical stage company developing advanced ophthalmic therapeutics, announced today that it has successfully completed a pre-IND meeting regarding the development plan for ST-100, Stuart’s first drug candidate for Dry Eye Disease (DED).  The meeting, held with the Food and Drug Administration’s Center

Read More